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Adrenocorticotrophic	hormone	(ACTH)-	secreting	pituitary	adenomas	give	rise	to	a	
severe endocrinological disorder, comprising Cushing’s disease, with multifaceted 
clinical	presentation	and	treatment	outcomes.	Experimental	studies	suggest	that	the	
disease variability is inherent to the pituitary tumour, thus indicating the need for 
further	studies	into	tumour	biology.	The	present	study	evaluated	transcriptome	
expression	pattern	in	a	large	series	of	ACTH-	secreting	pituitary	adenoma	specimens	in	
order	to	identify	molecular	signatures	of	these	tumours.	Gene	expression	profiling	of	
formalin-	fixed,	paraffin-	embedded	specimens	from	40	human	ACTH-	secreting	
pituitary	adenomas	revealed	the	significant	expression	of	genes	involved	in	protein	
biosynthesis and ribosomal function, in keeping with the neuroendocrine cell profile. 
Unsupervised cluster analysis identified 3 distinct gene profile clusters and several 
genes	were	uniquely	overexpressed	in	a	given	cluster,	accounting	for	different	
molecular	signatures.	Of	note,	gene	expression	profiles	were	associated	with	clinical	
features,	such	as	the	age	and	size	of	the	tumour.	Altogether,	the	findings	of	the	present	
study show that corticotroph tumours are characterised by a neuroendocrine gene 
expression	profile	and	present	subgroup-	specific	molecular	features.
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1  | INTRODUC TION
Cushing’s	 disease,	 that	 is	 adrenocorticotrophic	 hormone	 (ACTH)-	
secreting	pituitary	adenoma,	is	a	rare	and	complex	endocrine	disease.	
Hypersecretion	of	ACTH	by	the	tumour	gives	rise	to	excess	cortisol	
secretion by the adrenal glands, which, in turn, promotes a variety of 
clinical signs encompassing osteoporosis, muscle atrophy, hyperten-
sion	and	diabetes.	These	patients	carry	a	considerable	disease	burden,	
and mortality, if untreated, is high.1 Studies into the pathophysiology 
of corticotroph tumours have shed light on the involvement of individ-
ual	factors,	such	as	epidermal	growth	factor	(EGF),2	ubiquitin-	specific	
peptidase	8	(USP8),3,4	Brahma-	related	gene	1	(Brg-	1),5 although little 
is known about other, possible alterations in these tumours.
Of	note,	 an	 increasing	body	of	 evidence	 indicates	 that	ACTH-	
secreting adenomas differ markedly among themselves regarding 
their responses to the main modulators of corticotroph secretion, 
such	as	corticotrophin-	releasing	factor	and	steroids,6,7 as well as an-
cillary	modulators,	 such	 as	 vasopressin	 analogues,	 gonadotrophin-	
releasing hormone.8,9	Differences	in	in	vitro	ACTH	secretory	patterns	
have also been observed in response to dopamine or somatostatin Secure	 Array	 data	 link:	 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token= 
itsvwwkuzjyvpsj&acc=GSE93825
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receptor agonists,10,11 which obviously translates into different re-
sponsiveness to these drugs. Furthermore, somatic mutations and 
individual polymorphisms have been linked to differences in tumour 
size and secretory pattern.12,13
It	 is	therefore	apparent	that	wide-	range	evaluation	of	gene	ex-
pression patterns in corticotroph adenomas is needed to understand 
which features characterise tumoral corticotrophs and underlie the 
phenotypical diversity and thus, possibly, pave the way for a person-
alised	clinical	strategy.	The	present	study	evaluated	gene	expression	
profiles	 in	a	 large	series	of	human	ACTH-	secreting	adenomas.	We	
used	RNA	extracted	from	formalin-	fixed,	paraffin-	embedded	archi-
val samples collected during transsphenoidal surgery, thus overcom-
ing limitations as a result of the rarity of the disorder.
2  | MATERIAL S AND METHODS
2.1 | Sample collection
Forty	 formalin-	fixed,	 paraffin-	embedded	 adenomatous	 samples	
were retrieved and sections were microdissected under a surgical 
microscope. Specimens were collected from the centre of the biopsy 
to	minimise	RNA	degradation	as	a	 result	of	nucleic	acid	oxidation.	
Immunohistochemistry	 and	 neuropathological	 examination	 con-
firmed the diagnosis and the absence of normal pituitary tissue on 
sections.	MIB-	1	staining	was	<3%,	attesting	to	typical	corticotroph	
adenoma	(grade	I).	Overall,	specimens	had	been	stored	2-	15	years.	
Clinical data from patient presentation, surgical outcome and fol-
low-	up	were	collected.	The	entire	 series	comprised	9	men	and	31	
women,	 aged	 17–69	years,	 29	microadenomas	 (diameter	 ≤10	mm)	
and	11	macroadenomas	 (diameter	>10	mm),	6	surgical	 failures	and	
the	 remainder	surgical	 remissions.	Mean	±	SD	follow-	after	surgery	
up	was	140.3	±	13.6	months	 (range	2-	15	years).	The	study	was	ap-
proved	by	the	Ethical	Committee	of	the	Istituto	Auxologico	Italiano.
2.2 | RNA formalin- fixed, paraffin- embedded 
sample extraction
Four	20-	μm	thick	sections	from	each	specimen	were	extracted	using	
Recover	All	Total	Nucleic	Acid	Isolation	Kit	(Life	Technologies,	Carlsbad,	
CA,	USA).	 Tissue	 blocks	were	 deparaffinised	 in	 xylene,	 RNA-	bound	
proteins	removed	by	protease,	and	RNA	captured	on	glass-	filters	and	
eluted.	Recovery	of	RNA	averaged	1.5-	2	μg	per	sample.	To	maximise	
recovery	 of	 adequate	 transcripts	 and	 reduce	 RNA	 damage	 through	
oxydation,	slices	were	cut	from	the	center	of	the	paraffin	block.
2.3 | RNA quality control
RNA	(200	ng)	was	reverse-	transcribed	(Superscript-	Vilo	cDNA	syn-
thesis	kit;	Life	Technologies)	and	amplified	by	real-	time	polymerase	
chain	 reaction	 (PCR)	 for	 ribosomal	 protein	 L13A	 (RPL13A),14 using 
Taqman	 probe	 Hs03043885_g,	 (Applied	 Biosystems,	 Foster	 City,	
CA,	USA).	All	40	samples	yielded	the	expected	81-	bp	transcript	at	
<30	cycles,	attesting	to	adequate	quality	RNA.
2.4 | Whole genome- DASL HT
The	ILLUMINA	Whole	Genome	DASL	High-	Throughput	assay	(WG-	
DASL-	HT;	 Illumina,	 San	 Diego,	 CA,	 USA)	 for	 RNA	 extracted	 from	
formalin-	fixed,	 paraffin-	embedded	 tissues	 was	 used.	 The	 Human	
HT_12	v4	Bead	Chip	 evaluates	29	285	probes	 (20	815	genes)	 and	
is highly accurate with respect to estimating differences in gene 
expression	 by	 head-	to-	head	 comparison	 with	 quantitative	 real-	
time PCR.15	 Each	 sample	 carried	 300	ng	 of	 RNA.	 Fluorescence	
was	 imaged	and	data	captured	 into	HiScan,	a	high-	resolution	 laser	
imager	 (Illumina).	Microarray	data	have	been	deposited	with	Gene	
Expression	Omnibus	(accession	number	GSE93825).
2.5 | USP8 sequencing
Approximately	100	ng	of	RNA	was	reverse-	transcribed	(Superscript	
VILO	 cDNA	 synthesis	 kit;	 Life	 Technologies)	 with	 the	 oligonu-
cleotide	 primers:	 5′-	CTTGACCCAATCACTGGAAC-	3′	 (forward);	
5′-	TTACTGTTGGCTTCCTCTTCTC-	3′	(reverse)13 for amplification of 
USP8	exon	14,	the	most	frequent	site	of	mutations	reported	so	far.13 
Touch-	down	PCR	was	performed	using	GO	TAQ	DNA	polymerase	
(Promega,	 Madison,	 WI,	 USA)	 at	 64–57°C	 annealing.	 PCR	 prod-
ucts	were	 purified	 by	 ExoProStar	 Illustra	 enzyme	 (Ge	Healthcare,	
Chicago,	IL,	USA)	and	Sanger	sequencing	performed	using	the	ABI	
PRISM	 Big	 DYE	 Terminator	 V3.1	 cycle	 sequencing	 kit	 (Applied	
Biosystems)	on	ABI	PRISM	3500	analyser.
2.6 | Data analysis
Genome	Studio	software	(Illumina)	was	used	to	detect	genes	signifi-
cantly	 expressed	 in	 all	 specimens	 (ie,	 genes	with	 detection	P	<	0.05	
based	on	fluorescence	 intensity	 [average	signal]),	 thus	establishing	a	
common	expression	profile.	Subsequently,	we	attempted	 to	 identify	
different	 gene	 expression	 profiles	 in	 human	 corticotroph	 adenomas	
using	unsupervised	cluster	analysis.	This	approach	looks	for	similarities	
among	gene	expression	profiles	and	identifies	subgroups	of	samples	on	
the	basis	of	similarity	between	expression	profiles.16,17 Unsupervised 
methods for clustering among disease samples do not require prior 
knowledge on samples themselves or control tissues. Unsupervised 
cluster analysis was performed with hClust package (RStudio Inc., 
Boston,	MA,	USA)	using	 the	Ward	minimum	variance	method18 and 
patients	organised	 in	accordance	with	 their	gene	expression	profile.	
Dissimilarity between clusters was measured by Euclidean distance.
Comparisons	of	clinical	variables	between	clusters	(ANOVA	fol-
lowed	 by	 Fisher’s	 least	 significant	 difference	 or	 chi-	squared	 test,	
as	appropriate)	were	performed	with	statview,	version	4.5	(Abacus	
Concepts,	Berkeley,	CA,	USA).	P	<	0.05	was	considered	statistically	
significant.	Quantitative	variables	are	given	as	the	mean	±	SEM.
2.7 | Differential gene expression analysis
Once clusters had been established on the basis of similarity in 
gene	 expression	 profiles,	 differential	 gene	 expression	 analysis	
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enabled	the	identification	of	genes	that	are	expressed	to	a	greater	
or	 lesser	extent	 in	each	cluster.	Clusters	were	analysed	for	differ-
ential	expression	analysis	by	rank	invariant	normalisation	(Genome	
Studio;	Illumina).	Only	genes	with	Benjamini	and	Hochberg	P	≤	0.05	
were considered and Diff Scores were calculated based on P value 
transformation	 (ie,	 Diff	 Score	 ≥13	 [up-	regulated	 gene]	 and	 ≤−13	
[down-	regulated	 gene]	 P	=	0.05)	 according	 to	 the	 difference	 be-
tween	average	signals	in	reference	cluster	vs	the	other	2	clusters.	A	
Volcano	plot	was	used	to	illustrate	differential	expression	because	
it	visualises	the	magnitude	of	over-	and	underexpression	of	a	given	
gene	 plotted	 vs	 the	 significance	 of	 the	 comparison.	 This	 double-	
filtering	 approach	 allows	 significantly	 differentially	 expressed	
genes to be easily identified.19
2.8 | Real- time gene expression analysis
RNA	 (100	ng)	 was	 reverse-	transcribed	 (Superscript-	Vilo	 cDNA	
synthesis	 kit;	 Life	 Technologies)	 and	 quantitative	 real-	time	
PCR	was	performed	on	a	7900	HT	sequence	Detection	System	
(Applied	Biosystems),	using	Platinum	Quantitative	PCR	Supermix-	
UDG	 with	 premixed	 ROX.	 Taqman	 assay	 (Applied	 Biosystems)	
was used for detection of the following genes: BCAS2 (probe 
Hs00903014_g1),	SCG5	(probe	Hs00161638_m1),	IGFBP5 (probe 
Hs00181213_m1)	and	RPLP0	(probe	Hs99999902_m1).	Basal	ex-
pression data (2−ΔCt)	 were	 calculated	 and	 normalised	 to	RPLP0; 
differences	 between	 clusters	 were	 established	 by	 a	 Mann-	
Whitney	test.
2.9 | Functional annotation and Gene Ontology
Two	approaches	were	used	to	extract	biological	features	from	gene	
lists: david, version 6.720 was used to annotate and classify signifi-
cant	genes	and	perform	functional	annotation	clustering.	The	mini-
mum	value	of	the	enrichment	score	for	significant	clusters	was	≤1.3.	
Clusters	were	 annotated	 to	Gene	Ontology	 (GO)	 project,	 including	
Molecular	Function	(MF),	Cellular	Component	(CC),	Biological	Process	
(BP),	Kyoto	Encyclopaedia	of	Genes	and	Genomes	(KEGG)	and	Protein	
Information	Resource	 (SP_PIR).	 Furthermore,	cytoscape with Cluego 
plug-	in21	was	used	to	identify	molecular	interaction	networks.	The	bi-
ological	pathways	included	were:	GO	project,	KEGG	and	Inter	Pro	for	
protein domains.22 K	score	=	0.4	and	Benjamini	and	Hochberg	P value 
≤0.001	 were	 used	 for	 cytoscape	 analysis	 of	 significantly	 expressed	
genes. Of note, the group leading term is the most significant and 
genes can be included in several terms.22	The	size	of	nodes	reflects	
statistical significance of terms, whereas the degree of connectivity 
between	terms	(ie,	edge)	is	calculated	using	Kappa	statistics.23
3  | RESULTS
3.1 | Clustering analysis
Figure 1 shows unsupervised clustering and heat map profiling of 
significantly	 expressed	 genes	 in	 all	 40	 corticotroph	 adenoma	 sam-
ples.	Of	 20	815	 genes,	 1259	 genes	were	 expressed	 at	P	≤	0.05	 and	
formed	5	distinct	gene	groups	with	decreasing	expression.	Of	note,	
F IGURE  1 Unsupervised	clustering	of	1259	significantly	expressed	genes.	Colour	coding	of	gene	expression	values	is	shown	in	the	
upper left corner. USP8	mutation	status	is	indicated	to	the	left	of	the	heatmap:	white	squares	identify	wild-	type	sequence,	whereas	coloured	
squares indicate USP8	variants:	red,	variant	c.2159C>G;	green,	variant	c.2152T>C;	black,	variant	c.2155_2157delTCC;	yellow,	variant	
c.2157_2171delCCCAGATATAACCCA.	Height	of	nodes	represents	dissimilarity	between	clusters	as	measured	by	Euclidean	distance
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genes known to be associated with the corticotroph phenotype (eg, 
POMC, TBX19	[ie,	Tpit])	were	highly	expressed	(group	2).	Conversely,	
the	expression	of	genes	associated	with	other	anterior	pituitary	cells	
(for	example,	GH, PRL, PIT1, LHB, FSHB and CGA)	was	not	significant	
across specimens, thus confirming absent contamination by normal an-
terior pituitary tissue.24-26 Highest enrichment scores were annotated 
to	protein	biosynthesis,	ribosomes	and	RNA	processing	by	GO,	KEGG	
and	SP-	PIR	(see	Supporting	information,	Table	S1).	In	detail,	the	high-
est enrichment score was annotated to protein biosynthesis, followed 
by	ribosomal	function	in	group	1.	The	second-	ranked	cluster	revealed	
significant	enrichment	 in	 ribosomal	 function,	RNA	processing,	mem-
brane	transport	and	lumen,	ATP	metabolic	processes	and	cytoskeleton	
organisation.	Enrichment	scores	were	lower	in	groups	3	and	4,	mainly	
annotated to vesicle and lumen function, protein transport and locali-
sation. Enrichment in group 5 was the lowest, with lumen and protease 
the	only	annotated	functions	(see	Supporting	information,	Table	S1).
cytoscape	 analysis	 revealed	 that	 significantly	 expressed	 genes	
formed consistent networks related primarily to protein targeting 
to	 the	 endoplasmic	 reticulum	 (ER),	 cellular	 macromolecule	 meta-
bolic	 processes,	 RNA	 and	 polyRNA	 binding	 (Figure	2).	 Other	 net-
works were related to cellular transport of the protein to the ER 
and Golgi system and to membrane activity, such as vesicle forming 
and	coating.	Networks	related	to	post-	transcriptional	regulation	of	
gene	expression	and	the	energy	derivation	by	oxidation	of	organic	
compounds	were	also	 identified.	Altogether,	 functional	annotation	
by both approaches identified major enrichment of pathways re-
lated to protein synthesis and intracellular transport. Of note, this 
analysis	identified	genes	that	characterise	the	expression	profile	of	
corticotroph	adenomas	per	se,	and	not	genes	uniquely	expressed	in	
tumoral corticotrophs.
3.2 | Clinical data analysis
Gene	 expression	 profiles	 led	 to	 the	 grouping	 of	 patients	 in	 3	
separate	 clusters	 (ie,	 A,	 B	 and	 C).	 Analyses	 of	 differences	 in	
clinical variables among clusters revealed a higher proportion of 
F IGURE  2 cytoscape	analysis	showing	networks	formed	by	principal	significant	terms.	The	number	of	nodes	is	proportional	to	the	number	
of	the	term-	forming	genes;	nodes	are	colour-	coded	according	to	functional	annotations	and	can	have	more	than	1	colour	because	genes	may	
belong	to	more	than	1	term.	The	2	major	terms	are	shown	in	bold.	COPI,	coat	protein	I;	ER,	endoplasmic	reticulum
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macroadenomas	 and	 extrasellar	 tumours	 in	 cluster	 A	 (Table	1);	
indeed,	 91%	of	macroadenomas	 and	 92%	of	 extrasellar	 tumours	
from	the	entire	series	fell	in	cluster	A,	with	the	remainder	in	clus-
ter	B.	With	 respect	 to	a	quantitative	comparison	of	 tumour	 size,	
adenomas	 in	 cluster	 A	were	 bigger	 than	 those	 in	 clusters	 B	 and	
C, although this failed to reach statistical significance (F	=	1.88,	
not	 significant).	 Patients	 in	 cluster	 A	were	 also	 older	 (F	=	3.258,	
P	<	0.05)	(Table	1),	although	age	and	tumour	diameter	were	not	as-
sociated with each other (r	=	0.01,	not	significant).	No	differences	
regarding hormonal values, pathological findings and surgical out-
comes	were	detected	among	clusters	(Table	1).
3.3 | USP8 sequencing
Five patients presented USP8 variants: 2 patients showed mis-
sense	 variant	 rs672601311	 (c.2159C>G,	 p.720Pro>Arg),	 1	 patient	
showed	missense	variant	rs672601307	(c.2152T>C,	p.718Ser>Pro),	
1	 patient	 showed	 the	 3-	bp	 deletion	 variant	 rs672601306	
Cluster A Cluster B Cluster C Significance
Demographical features
	Sex	distribution	 
(male/female)
5/15 2/14 2/2 NS
	Age	(years) 45.1	±	3.01 36.7 ± 3.18 30.3	±	3.74 P	<	0.05
Hormonal parameters
 Urinary free cortisol 
(μg	24	h-1)
547.4	±	153.4 690.9 ± 120.8 474.7	±	179.2 NS
	Plasma	ACTH	(pg	mL-1) 89.2 ± 13.9 63.1 ± 6.15 45.3	±	3.22 NS
 Morning serum 
cortisol (μg dL-1)
23.5 ± 1.28 19.6 ± 1.60 18.5 ± 2.20 NS
 Midnight serum 
cortisol (μg dL-1)
20.5	±	1.48 19.8 ± 2.52 18.2 ± 6.00 NS
 Cortisol after 1 mg of 
dexamethasone	
(μg dL-1)
16.5 ± 1.98 15.5 ± 2.83 7.95	±	4.55 NS
 Cortisol suppression 
after	8	mg	dexameth-
asone	(%	baseline)
34.9	±	9.44 43.0	±	13.51 11.6 ± 1.81 NS
	ACTH	peak	after	
corticotrophin-	
releasing	hormone	(%	
baseline)
341.9	±	93.8 271.5	±	79.4 392.1	±	57.4 NS
	Macroadenoma	(%) 50% 6.2% 0% P	<	0.005
	Extrasellar	extension	
(%)
55% 6.2% 0% P	<	0.005
Pathology findings
	Tumour	diameter	(mm) 10.1 ± 1.52 7.0	±	0.64 6.7 ± 0.25 NS
	ACTH	immunoreactive	
cells	(%)
86.0	±	2.48 84.1	±	3.54 93.7 ± 1.25 NS
 Crooke cells (absent/
slight/moderate)
45%/45%/10% 69%/25%/6% 75%/25%/0% NS
 Cellular atypia 
(absent/slight)
55%/45% 75%/25% 100%/0% NS
Surgical outcomes
	Immediate	remission	(%) 85% 87.5% 100% NS
	Relapse	(%) 6% 0% 0% NS
 Length on steroid 
replacement therapy 
(months)
19.3 ± 5.9 16.9 ± 3.5 23.2 ± 12.1 NS
Data	 are	 the	 mean	±	SEM	 or	 percentage.	 ACTH,	 adrenocorticotrophic	 hormone;	 NS,	 not	
significant.
TABLE  1 Hormonal and clinical 
variables in individual patient clusters
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(c.2155_2157delTCC,	 p.Ser718del)	 and	 1	 patient	 showed	 a	 novel,	
15-	bp	 deletion	 (c.2157_2171delCCCAGATATAACCCA,	 p.Pro720_
Gln724del).	 Gene	 expression	 profiles	 in	 specimens	 bearing	 USP8 
variants	did	not	group	together,	except	for	the	2	specimens	with	the	
same	missense	variant,	which	clustered	next	to	each	other	(Figure	1).
3.4 | Differentially expressed genes
Comparisons of gene profiles from the 3 different clusters allowed 
identification	of	over-	or	under-	expressed	genes	between	clusters.	
A	Volcano	plot	(Figure	3)	shows	genes	up-	regulated	with	Diff	Score	
≥13	and	genes	down-	regulated	with	Diff	Score	≤−13	between	clus-
ter	A	vs	clusters	B	and	C	(Figure	3A),	cluster	B	vs	clusters	A	and	C	
(Figure	3B),	and	cluster	C	vs	clusters	A	and	B	(Figure	3C).
Of	 1259	 significantly	 expressed	 genes,	 4	 genes	 were	 uniquely	
overexpressed	 in	 cluster	 A,	 313	 genes	 were	 overexpressed	 only	
in	cluster	B	and	29	genes	overexpressed	only	 in	cluster	C	 (Table	2).	
Among	the	4	genes	uniquely	overexpressed	in	cluster	A,	3	genes	were	
associated with tumoral processes (ie, BCAS2 [breast carcinoma am-
plified sequence 2] and RPS6KA6 [ribosomal protein S6 kinase 6] with 
breast cancer27,28 and RBX1	[ringbox	1]	with	gastric	and	lung	cancer).	
With	 regard	 to	 genes	 overexpressed	 in	 cluster	 B	 compared	 to	 the	
other	2	clusters,	we	observed	overexpression	of	the	POMC gene itself, 
as well as of SCG5, which encodes for secretogranin 5 (also known as 
neuroendocrine	 protein	 7B2)	 associated	 with	 prohormone	 conver-
tase 2 activation.29 Furthermore, genes involved in neuroendocrine 
tumours (eg, NOTCH3, LGALS3, PITX1 and NGRN)	were	also	overex-
pressed	in	cluster	B	compared	to	clusters	A	and	C.	Additional	genes	
of interest to corticotroph adenoma pathophysiology were RXRB and 
TIMP1 in view of their links to retinoic acid sensitivity30,31	and	matrix	
metalloproteinase, respectively.32,33 Given the number of genes over-
expressed	 in	 this	 cluster,	we	 could	perform	 functional	 analysis	 and	
detected significant enrichment for 123 genes. Highest enrichment 
scores were relative to ribosomal function and translation (enrichment 
4.89),	ribosome	assembly	(enrichment	1.97),	protein	biosynthesis	(en-
richment	1.67)	 and	mRNA	processing	 (enrichment	1.60),	 thus	 com-
prising items recurring with features identified for functional analysis 
of	all	corticotroph	adenomas	(see	Supporting	information,	Table	S1).	
The	remaining	190	genes	did	not	fall	into	specific	functional	annota-
tion	groups.	Gene	expression	profiles	in	4	patients	differed	markedly	
from	all	others	and	clustered	separately	 (cluster	C).	Amongst	genes	
uniquely	overexpressed	 in	 this	 cluster	 (Table	2),	 IGFBP5	 (insulin-	like	
growth	factor	binding	protein	5)	and	genes	associated	with	intracellu-
lar	calcium	flux	(ie,	CALCOCO1, CAMTA2)	appeared	to	be	considerably	
overexpressed	as	measured	by	fold-	change	vs	other	clusters	and	as	of	
interest to tumoral corticotroph pathophysiology.
F IGURE  3 Volcano	plot.	Genes	up-	and	down-	regulated	in	the	
3	clusters.	Effect	(average	signal,	AVG)	is	shown	on	the	x-	axis	and	
significance	(Diff	Score)	is	shown	on	the	y-	axis.	Up-	regulated	genes	
appear	to	the	right	and	down-	regulated	genes	appear	to	the	left	
of the x-	axis.	(A)	Comparison	between	cluster	A	and	clusters	B	
and	C.	(B)	Comparison	between	cluster	A	and	clusters	A	and	C.	(C)	
Comparison	between	cluster	C	and	clusters	A	and	B.	Significant	
genes	are	highlighted	in	red	(Diff	Score	>13)	and	selected	genes	are	
identified by name
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TABLE  2 Genes	up-	regulated	in	individual	clusters
Symbol Diff Score Definition
Cluster	A
 BCAS2 22,57 Homo sapiens	breast	carcinoma	amplified	sequence	2,	mRNA
 RPS6KA6 15,18 Homo sapiens	ribosomal	protein	S6	kinase,	90	kDa,	polypeptide	6,	mRNA
 RBX1 13,5 Homo sapiens	ringbox	1,	mRNA
 FAM155A 13,2 Homo sapiens	family	with	sequence	similarity	155,	member	A,	mRNA
Cluster B	(first	20	genes	with	highest	Diff	Scores	listed	here,	the	entire	list	is	given	in	the	Supporting	information,	Table	S2)
 RAB33B 64,25 Homo sapiens	RAB33B,	member	RAS	oncogene	family,	mRNA
 RAX2 64,25 Homo sapiens	retina	and	anterior	neural	fold	homeobox	2,	mRNA
 EIF2AK4 54,75 Homo sapiens	eukaryotic	translation	initiation	factor	2	alpha	kinase	4,	mRNA
 RBM25 51,91 Homo sapiens	RNA	binding	motif	protein	25,	mRNA
 ZNF358 51,62 Homo sapiens	zinc	finger	protein	358,	mRNA
 ACTR1A 49,43 Homo sapiens	ARP1	actin-	related	protein	1	homolog	A,	mRNA
 SCG5 49,18 Homo sapiens	secretogranin	V	(7B2	protein),	mRNA
 NT5C2 48,13 Homo sapiens	5′-	nucleotidase,	cytosolic	II,	mRNA
 BTBD2 47,99 Homo sapiens	BTB	(POZ)	domain	containing	2,	mRNA
 TNPO2 46,04 Homo sapiens	transportin	2,	mRNA
 UBXN2A 45,06 Homo sapiens	UBX	domain	protein	2A,	mRNA
 SH3YL1 43,87 Homo sapiens	SH3	and	SYLF	domain	containing	1	(SH3YL1),	mRNA
 HNRNPUL2 43,84 Homo sapiens	heterogeneous	nuclear	ribonucleoprotein	U-	like	2,	mRNA
 HARS2 43,51 Homo sapiens	histidyl-	tRNA	synthetase	2,	mitochondrial,	mRNA
 DARS 43,26 Homo sapiens	aspartyl-	tRNA	synthetase,	mRNA
 RNGTT 43,15 Homo sapiens	RNA	guanylyltransferase	and	5′-	phosphatase,	mRNA
 NDUFS8 42,47 Homo sapiens	NADH	dehydrogenase	(ubiquinone)	Fe-	S	protein	8,	23	kDa	
(NADH-	coenzyme	Q	reductase),	mRNA
 THBS3 42,47 Homo sapiens	thrombospondin	3,	mRNA
 FOXO4 41,59 Homo sapiens	forkhead	box	O4	(FOXO4),	mRNA
 GCN1 41,08 Homo sapiens eIF2 alpha kinase activator homolog, also known as general 
control	of	amino-	acid	synthesis	1-	like	1	(GCN1L1),	mRNA
Cluster C
 SNX29P1 15,12 Homo sapiens	sorting	nexin	29	pseudogene	1,	also	known	as	RUN	domain	
containing	2B,	mRNA	(RUNDC2B)
 IGFBP5 14,78 Homo sapiens	insulin-	like	growth	factor	binding	protein	5,	mRNA
 PLD2 14,78 Homo sapiens	phospholipase	D2,	mRNA
 SNORA54 14,34 Homo sapiens	small	nucleolar	RNA,	H/ACA	box	54,	small	nucleolar	RNA
 SNORD1141 14,30 Homo sapiens	small	nucleolar	RNA,	C/D	box	114-	1,	small	nucleolar	RNA
 ACIN1 14,28 Homo sapiens	apoptotic	chromatin	condensation	inducer	1,	mRNA
 SNORA10 14,18 Homo sapiens	small	nucleolar	RNA,	H/ACA	box	10,	small	nucleolar	RNA
 SNORD104 14,05 Homo sapiens	small	nucleolar	RNA,	C/D	box	104,	small	nucleolar	RNA
 SNORD41 13,86 Homo sapiens	small	nucleolar	RNA,	C/D	box	41,	small	nuclear	RNA
 SNORA73B 13,74 Homo sapiens	RNA,	U105A	small	nucleolar,	small	nucleolar	RNA	a.k.a	RNU105A
 CALCOCO1 13,71 Homo sapiens	calcium	binding	and	coiled-	coil	domain	1,	mRNA
 SCAF1 13,69 Homo sapiens	SR-	related	CTD-	associated	factor	1,	mRNA
 SNORA64 13,65 Homo sapiens	small	nucleolar	RNA,	H/ACA	box	64,	small	nucleolar	RNA
 CAMTA2 13,49 Homo sapiens	calmodulin	binding	transcription	activator	2,	mRNA
 SNORA73B 13,45 Homo sapiens	small	nucleolar	RNA,	H/ACA	box	73B,	small	nucleolar	RNA
 ARSG 13,42 Homo sapiens	arylsulfatase	G,	mRNA
(Continues)
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Real-	time	PCR	confirmed	overexpression	of	BCAS2	in	cluster	A,	
SCG5 in cluster B and IGFBP5	in	cluster	C	(Figure	4),	in	support	of	the	
differential	expression	observed	with	respect	to	microarray	data.
4  | DISCUSSION
ACTH-	secreting	pituitary	tumours	are	a	rare	and	poorly	understood	
disease.	 The	 studies	 performed	 so	 far	 in	 adenomatous	 specimens	
have indicated the involvement of individual genes (ie, mutations in 
USP8)3,4	and	the	variable	expression	of	factors	that	mediate	sensi-
tivity to glucocorticoids, such as HSP90, BRG-1 and HSD11B2.5,34,35 
Furthermore, cellular models derived from rat or dog tumoral cor-
ticotrophs called EGF36	 and	 testicular	 orphan	 nuclear	 receptor	 4	
(TR4)37 into play. Studies in zebrafish also linked the development 
of	pro-	opiomelanocortin	(POMC)-	cell	tumours	to	pituitary	tumour-	
transforming gene (PTTG)	 overexpression.38	 Altogether,	 several	
mechanisms appear to be involved in corticotroph tumorigenesis, 
although	a	clear-	cut	picture	of	the	changes	occurring	in	corticotroph	
tumours is as yet missing.
The	present	study	had	2	main	aims:	identifying	gene	expression	
patterns characteristic to tumoral corticotrophs and evaluating dif-
ferences in among corticotroph adenoma subgroups. Over recent 
decades,	 it	 has	 become	 increasingly	 evident	 that	 ACTH-	secreting	
adenomas differ considerably among themselves, in terms of se-
cretory	parameters	and	responses	to	medical	therapy.	Thus,	studies	
investigating the variability of these tumours are necessary to iden-
tify the features associated with tumour subtypes and to aid in the 
development of targeted therapeutical approaches.
Heatmap	 profiling	 revealed	 the	 significant	 expression	 of	 1259	
of 29 285 probes in corticotroph adenoma specimens. Obviously, 
genes associated with the corticotroph phenotype (ie, POMC, 
TBX19)	were	among	the	highly	expressed	genes39,40 Other genes as-
sociated	with	POMC-	processing	(ie,	proprotein	convertase	inhibitor	
[PCSKIN], secretogranin [SCG5], cathepsin L1 [CTSL1]),	 with	 drug	
action	on	corticotrophs	 (ie,	 retinoid	X	receptors	 [RXRB],	GABA	re-
ceptors [GABARAPL2, GABRB3]),	or	with	steroid	 feedback	 (ie,	11β-	
hydroxysteroid	dehydrogenase	 [HSD11BIL]),	were	also	significantly	
expressed.	As	regards	the	individual	genes	noted	above,	the	expres-
sion of HDAC2, SMARCA4 (ie, formerly BRG-1)	TR4, FGFR4 and EGF 
or EGFR	was	not	included	among	the	significantly	expressed	genes	in	
the	corticotroph	adenoma	set;	PPTG1-	interacting	protein	(PTTG11P)	
was	significantly	expressed,	although	PTTG itself was not. Likewise, 
several	members	 of	 the	 heat	 shock	 protein	 family	 A	 (HSP70)	 (eg,	
HSPA8, HSPA9)	were	detected,	although	there	were	none	related	to	
heat	 shock	 protein	 alpha	 family	 (HSP90).	 Furthermore,	 given	 that	
the response to vasopressin, somatostatin and dopamine receptor 
agonists	in	Cushing’s	disease	has	been	linked	to	specific	receptor	ex-
pression,8,10,11	we	sought	evidence	for	the	significant	expression	of	
these receptors, however none proved significant.
Several	 genes	 detected	 at	 normal	 human	 pituitary	 expression	
profiling41 were also found in tumoral corticotrophs, such as PUM1 
(pumilio	homolog	1),	TPT1 (tumour protein translationally controlled 
1)	and	CDK2AP1	(cyclin-	dependent	kinase	2-	associated	protein	1),	as	
were some genes detected in other pituitary tumours,42-44 such as 
AKT2	 (v-	akt	murine	thymoma	viral	oncogene	homolog	2),	NOTCH3 
(Notch	homolog	3)	and	PITX1	 (paired-	like	homeodomain	transcrip-
tion	factor	1).	Our	data	confirmed	some	of	the	findings	obtained	in	
7 corticotroph macroadenomas with the UniGEM microarray probe 
on some 7000 genes25	 (ie,	 overexpression	 of	 HSPH1, SH3BGRL2 
and RGS2, with the latter being of particular interest because it in-
creases	during	corticotrophin-	releasing	hormone	incubation	in	mu-
rine	 tumoral	 corticotrophs).45 Moreover, we confirmed the results 
obtained	in	12	corticotroph	adenomas	reporting	the	expression	of	
several genes (eg, SEZ6L, CALY, CD200, TCF7L2, NISCH, RUNDC3A 
and NGFRAP1).46	 We	 could	 also	 confirm	 increased	 expression	 of	
cold-	inducible	RNA	binding	protein	(CIRP),	recently	proven	to	stim-
ulate murine corticotroph tumour growth47 and KRT8 (ie, keratin 8 
Symbol Diff Score Definition
 SNORA32 13,36 Homo sapiens	small	nucleolar	RNA,	H/ACA	box	32,	small	nucleolar	RNA
 RNU5A 13,31 Homo sapiens	RNA,	U5A	small	nuclear,	small	nuclear	RNA
 SNORD12 13,30 Homo sapiens	small	nucleolar	RNA,	C/D	box	12,	small	nucleolar	RNA
 RNU1G2 13,24 Homo sapiens	RNA,	U1G2	small	nuclear,	small	nuclear	RNA
 PPID 13,23 Homo sapiens	peptidylprolyl	isomerase	D,	mRNA
 SNORD3D 13,19 Homo sapiens	small	nucleolar	RNA,	C/D	box	3D,	small	nucleolar	RNA
 SNORD33 13,16 Homo sapiens	small	nucleolar	RNA,	C/D	box	33,	small	nucleolar	RNA
 SNORD68 13,14 Homo sapiens	small	nucleolar	RNA,	C/D	box	68,	small	nucleolar	RNA
 SNORD110 13,11 Homo sapiens	small	nucleolar	RNA,	C/D	box	110,	small	nucleolar	RNA
 SCARNA3 13,05 Homo sapiens	small	Cajal	body-	specific	RNA	3,	guide	RNA
 KMT5A 13,05 Homo sapiens	lysine	methyltransferase	5A,	also	known	as	SET	domain	
containing 8 (SETD8),	mRNA
 SNORD66 13,02 Homo sapiens	small	nucleolar	RNA,	C/D	box	66,	small	nucleolar	RNA
 SNORA71A 13,01 Homo sapiens	small	nucleolar	RNA,	H/ACA	box	71A,	small	nucleolar	RNA
TABLE  2  (Continued)
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or	CAM	5.2),	which,	together	with	significant	expression	of	LGALS3, 
represents a immunophenotype marker for corticotroph tu-
mours.48-50 Furthermore, our results corroborate those obtained in 
9	adenomas	by	RNA	sequencing	on	32	186	protein-	coding	genes,51 
which	revealed	the	significant	expression	of	a	variety	of	genes,	some	
with clear links to neuroendocrine or pituitary tumoral phenotype 
(eg, CGA, FILIP1, PITX1, IGFBP5)	 and	 others	with	 as	 yet	 unknown	
links to corticotroph tumour development (eg, FBOXO31, FZD7, 
GPX3, MYH6).	Our	data	also	matched	the	results	obtained	in	ectopic	
ACTH-	secreting	tumours52	(ie,	significant	expression	of	MAX	dime-
risation	 protein	 4	 [MXD4], neugrin [NGRN] and SHC transforming 
protein 1 [SHC1]).
Most	recent	studies	have	revealed	that	up	to	60%	of	human	pi-
tuitary	ACTH-	secreting	adenomas	may	harbour	somatic	mutations	
in	the	ubiquitin-	specific	protease	8	(ie,	USP8)	gene3,4 and, indeed, 5 
specimens in our series presented USP8	variants.	The	detected	mu-
tations were either missense or deletion variants and fell within the 
14-	3-	3	 binding	motif	 of	USP8 suggesting enhanced USP8 activity, 
as most frequently occurs.3,4 Interestingly, the 2 specimens carrying 
the	same	variant	clustered	next	to	each	other,	indicating	highly	sim-
ilar	gene	expression	profiles,	whereas	the	3	remaining	variants	were	
associated	with	differing	expression	profiles	and	 fell	 into	separate	
clusters. It appears that, although variants appear to lead to a defect 
in	USP8	activity,	the	resulting	gene	expression	profile	may	diverge;	
indeed, catalytic activity of USP8 mutants reportedly differs.3
As	regards	enrichment	analysis,	pathways	involved	in	protein	bio-
synthesis,	macromolecule	metabolic	processes	and	RNA	processing	
appeared to be the most significant, in keeping with a neuroendo-
crine, secretory phenotype. Pathways associated with cell death and 
DNA	repair	ranked	amongst	the	low	enrichment	scores,	as	expected	
given the benign nature of these tumours. Of note, there was little 
overlap with pathways involved in prolactinomas53 and nonsecreting 
pituitary adenomas.54
Lastly,	 differential	 expression	 analysis	 was	 able	 to	 identify	
genes	uniquely	expressed	in	each	of	the	3	clusters	formed	by	un-
supervised clustering analysis. Interestingly, although POMC is 
obviously	significantly	expressed	in	all	specimens,	it	proved	to	be	
overexpressed	together	with	the	POMC-	processing	co-	adjuvator	
SCG5 in specimens grouping in cluster B compared to those in 
clusters	A	and	C.	Increased	expression	of	genes	involved	in	other	
pituitary	 tumours	 or	 ACTH-	secreting	 neuroendocrine	 tumours,	
most notably NOTCH3, PITX1, LGALS3 and NGRN,38,43,44,52 was 
also observed in cluster B. Furthermore, adenomas in this clus-
ter	overexpressed	the	retinoid	X	receptor	beta	gene	(RXRB),	thus	
confirming	possibly	greater	sensitivity	to	RXR	agonists30,31 in se-
lected adenomas. TIMP1	(tissue	metallopeptidase	inhibitor	1)	was	
also	overexpressed	in	cluster	B	adenomas,	which	is	an	interesting	
result	 given	 the	 recent	 reports	 on	 matrix	 metalloproteinase-	932 
and	TIMP1	itself33 in corticotroph adenomas.
Four	 adenomas	presented	 a	markedly	different	 gene	expres-
sion	phenotype	and	clustered	separately	 (cluster	C).	 IGFBP5 was 
among	the	genes	highly	overexpressed	in	this	cluster,	which	may	
prove to be of particular interest given its role in both carcino-
genesis and normal cell growth.55 Indeed, IGFBP5 is known to 
be	 expressed	 in	 the	 pituitary	 itself,	 independently	 from	 growth	
hormone-	producing	cells,56	and,	furthermore,	IGFBP5	expression	
and protein synthesis was increased in a subset of nonfunction-
ing pituitary adenomas.57	Lastly,	overexpression	of	BCAS2 (breast 
carcinoma	amplified	sequence	2)	and	RPS6KA6 (ribosomal protein 
S6	kinase	6),	both	associated	with	the	tumour	suppressor	p53,27,28 
as well as RBX1	(ringbox	1),	a	gene	linked	to	cullin-	modulated	cell	
cycle progression58,	was	detected	in	cluster	A;	p53	itself	has	been	
F IGURE  4 Quantitative	expression	of	selected	genes	in	
different	clusters.	(A)	Expression	of	BCAS2	in	cluster	A	vs	other	
clusters.	(B)	Expression	of	SCG5	in	cluster	B	vs	other	clusters.	(C)	
Expression	of	IGFBP5 in cluster C vs other clusters
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shown	to	accumulate	 in	a	subset	of	pituitary	ACTH-	secreting	 le-
sions, in particular invasive adenomas.59	Accordingly,	we	observed	
that	 patients	 in	 cluster	 A	 presented	 the	 highest	 prevalence	 of	
macroadenomas	 and	 invasive	 tumours	 and	 both	 p53	 and	 cullin-	
RING pathways represent attractive therapeutic targets.58	A	 re-
cent study aimed at identifying the genetic signature of invasive 
macroadenomas	reported	an	increased	expression	of	CCND2 (cy-
clin	2)	and	ZNF676	(zinc-	finger	protein	676)	in	3	invasive	adenomas	
compared	to	non-	invasive	corticotroph	adenomas.46 Not surpris-
ingly,	neither	gene	was	significantly	expressed	in	our	series,	which	
comprised 12 invasive adenomas, because our study aim differed 
and	 required	 an	 unforced	 approach	 to	 gene	 expression	 analysis	
(ie,	 unsupervised	 clustering	without	 a	 priori	 classification);	 addi-
tional	studies	 into	 this	as	well	as	other	group-	derived	signatures	
will	allow	the	above	results	to	be	extended	and	confirmed.
In	conclusion,	the	present	study	describes	the	gene	expression	
profile	of	human	pituitary	ACTH-	secreting	adenomas	and	has	iden-
tified	genes	associated	with	distinct	expression	clusters.	Overall,	 it	
appears that these tumours present a neuroendocrine cell profile 
but,	at	the	same	time,	there	are	clearly	distinct	gene	expression	pat-
terns	 in	 individual	subgroups.	This	evidence	provides	 the	basis	 for	
future studies into the molecular pathophysiology of these adeno-
mas and, possibly, paves the way to target therapy.
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